188 related articles for article (PubMed ID: 37244946)
41. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
42. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Wang H; Xu B; Shi J
Gene; 2020 Jan; 722():144076. PubMed ID: 31454538
[TBL] [Abstract][Full Text] [Related]
43. PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/β-catenin Pathway.
Jin W; Wang X
Ann Clin Lab Sci; 2022 May; 52(3):359-366. PubMed ID: 35777795
[TBL] [Abstract][Full Text] [Related]
44. The m
Huang Z; Luo C; Hou X; Yu D; Su Y; Li X; Luo Y; Liao G; Mu J; Wu K
Pediatr Surg Int; 2023 Feb; 39(1):126. PubMed ID: 36790471
[TBL] [Abstract][Full Text] [Related]
45. METTL3-mediated m
Wu Y; Chang N; Zhang Y; Zhang X; Xu L; Che Y; Qiao T; Wu B; Zhou Y; Jiang J; Xiong J; Zhang J; Zhang J
J Exp Clin Cancer Res; 2021 Mar; 40(1):90. PubMed ID: 33676554
[TBL] [Abstract][Full Text] [Related]
46. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
47. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
48. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
[TBL] [Abstract][Full Text] [Related]
50. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
51. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Meng H; Zhao B; Wang Y
Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
[TBL] [Abstract][Full Text] [Related]
52. miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer.
Wu H; Li F; Zhu R
Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):304-316. PubMed ID: 33355622
[TBL] [Abstract][Full Text] [Related]
53. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
[TBL] [Abstract][Full Text] [Related]
54. METTL3 preferentially enhances non-m
Wei X; Huo Y; Pi J; Gao Y; Rao S; He M; Wei Q; Song P; Chen Y; Lu D; Song W; Liang J; Xu L; Wang H; Hong G; Guo Y; Si Y; Xu J; Wang X; Ma Y; Yu S; Zou D; Jin J; Wang F; Yu J
Nat Cell Biol; 2022 Aug; 24(8):1278-1290. PubMed ID: 35927451
[TBL] [Abstract][Full Text] [Related]
55. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
56. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
[TBL] [Abstract][Full Text] [Related]
57. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
[TBL] [Abstract][Full Text] [Related]
58. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
Li S; Lu X; Zheng D; Chen W; Li Y; Li F
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010
[TBL] [Abstract][Full Text] [Related]
59. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
[TBL] [Abstract][Full Text] [Related]
60. METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
Chen JX; Chen DM; Wang D; Xiao Y; Zhu S; Xu XL
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36960869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
